John Harkess, MD
Infectious Disease · Oklahoma City, OKNPI 1366496218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Insmed, Inc. at 31.6% of the total. Reporting peaked in 2019 at $537 and has fallen 94.7% since, to $28 in 2023.
Across 63 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$366
- AbbVie$188
- Merck$159
- Boehringer Ingelheim$108
- Vyera Pharmaceuticals, LLC$53
- Regeneron Healthcare Solutions, Inc.$41
- plus $243 from 14 others
What the payments were for
- Food & beverage$1,04390%
- Education$11510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 16 | $366 |
| AbbVie(2 entities) | 10 | $188 |
| Merck | 11 | $159 |
| Boehringer Ingelheim | 6 | $108 |
| Vyera Pharmaceuticals, LLC | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
| Harmony Biosciences LLC | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| AstraZeneca | 1 | $16 |
| GSK | 1 | $15 |
| Amgen | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$108
How this compares
$1,158 in reported general payments places this provider in the 65th percentile of 51 infectious disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Oklahoma City
- Ahmad AshfaqOklahoma City$22K
- Erin McBrideOklahoma City$6K
- Amaury DiazOklahoma City$5K
- Bushra SiddiqueOklahoma City$3K
- Andrea ScottOklahoma City$3K
- Janki AminOklahoma City$3K
- David ChansolmeOklahoma City$2K
- Miranda McGheeOklahoma City$2K
- Cade ParkeOklahoma City$1K
- Maria AlkozahOklahoma City$829
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.